Inflammation - a biological basis for heavy menstrual bleeding, dysmenorrhea and CNS disorders. Integrated solution
https://doi.org/10.21518/2079-701X-2015-XX-20-27
Abstract
The review tells about disorders which cause uterine bleeding clinically manifested in heavy menstrual bleeding combined with dysmenorrhea and changes in the central nervous system. The key pathogenetic cause of bleeding associated with endometrial dysfunction is inflammation. Hormonal therapy, being the first-choice treatment, provides a comprehensive effect on the interrelated mechanisms, demonstrates high efficacy and allows for preservation of the uterus.
About the Authors
G. E. Chernukha
Scientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, the Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
L. M. Ilyina
Association of Gynecologists Endocrinologists, Moscow
Russian Federation
Russian Federation
References
1. Jensen JT, Lefebvre P, LaLiberte F et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt), 2012, 21: 539-547.
2. Bonafede MM, Miller JD, Lukes AS et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. ClinicoEconomics and Outcomes Research, 2014, 6: 423-429.
3. Palep-Singh M, Prentice A: Epidemiology of abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol, 2007, 21(6): 887-890.
4. Shapley M, Jordan K, Croft PR: An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract., 2004, 54(502): 359-36.
5. Cooper K, Lee A, Chien P et al. Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: Retrospective analysis of hospital episode statistics in Scotland. BJOG, 2011, 118(10): 1171-1179.
6. Heavy menstrual bleeding. Clinical guideline 44. London National Institute for Health and Clinical Excellence, January 2007.
7. Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol 2013, 122: 176-185.
8. Management of acute abnormal uterine bleeding in non-pregnant women. Committee Opinion №557. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013, 121: 891-6.
9. Singh S, Best C, Dunn S, et al. Abnormal Uterine Bleeding in Pre-Menopausal Women. JOGC 2013, 35(5) (Suppl 1):1-28.
10. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006, 108(2): 428-41.
11. Lefebvre G, Pinsonneault O, Antao V, et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005, 27(12): 1117-46.
12. Munro MG, Critchley HOD, Brode Ms, Fraser IS, for the FIGO Working Group on Menstrual Disorders. Intern. SPECIAL COMMUNICATION. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. J Gynecol Obstet 2011, 113:3-13.
13. Critchley HOD, Kelly RW, Baird DT, Brenner RM. Regulation of human endometrial function: mechanisms relevant to uterine bleeding. Review. Reprod Biol Endocrinol 2006, 4(Suppl 1): S5.
14. Critchley HOD, Osei J, Henderson TA, et al. Hypoxia-Inducible Factor-1 Expression in Human Endometrium and Its Regulation by Prostaglandin E-Series Prostanoid Receptor 2 (EP2). Endocrinology 2006, 147(2): 744-75.
15. Maybin JA, Critchley HO. Progesterone: a pivotal hormone at menstruation. Ann NY. Acad Sci 2011, 1221: 88-97.
16. Maybin JA, Hirani N, Brown P, Jabbour HN, Critchley HO. The Regulation of Vascular Endothelial Growth Factor by Hypoxia and Prostaglandin F2a during Human Endometrial Repair. J Clin Endocrinol Metab 2011, 96: 2475-2483.
17. Berbic M, Ng CH, Fraser IS. Inflammation and endometrial bleeding. Climacteric 2014, 17 (Suppl 2): 47-53.
18. Menzies FM, Shepherd MC, Nibbs RJ, Nelson SM. The role of mast cells and their mediators in reproduction, pregnancy and labour. Hum Reprod Update 2011, 17(3): 383-396.
19. Salamonsen LA, Lathbury LJ. Endometrial leukocytes and menstruation. Hum Reprod Update 2000, 6: 16-27.
20. Kayisli UA, Guzeloglu-Kayisli O, Arici A. Endocrine immune interactions in human endo-metrium. Ann N YAcad Sci 2004, 1034: 50-63.
21. Pockaj BA, Basu GD, Pathangey LB et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prosta-glandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004, 11: 328-39.
22. Malik S, Day K, Perrault I, et al. Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual endometri-um and effluent in women with menorrhagia. Hum Reprod 2006, 21: 2158-66.
23. Latthe P, Mignini L, Gray R et al. Factors predisposing women to chronic pelvic pain: systematic review. BMJ 2006, 332: 7475.
24. Fraser IS, Critchley HO and Munro MG, et al. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev Obstet Gynecol 2009, 4(2): 179-89.
25. Liu Z, Doan OV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007, 10(3): 183-94.
26. Vahdat Shariatpanaahi M, Moshtaaghi M, Shahbaazi SH et al. The relationship between depression and serum ferritin level. Eur J Clin Nutr 2007, 61: 532-535.
27. Murrey-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 2007, 85: 778-87.
28. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65: 732-741.
29. Messay B, Lim A, Marslandet AL. Current understanding of the bi-directional relationship of major depression with inflammation. Biol of Mood&Anxity Disord 2012, 2: 4.
30. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67: 446-457.
31. Howren MB, Lamkin DM, Suls J, et al. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71: 171-186.
32. Poon DC, Ho YS, Chiu K, Chang RC. Cytokines: how important are they in mediating sickness? Neurosci Biobehav Rev 2013, 37: 1-10.
33. Cooper K, Lee A, Chien P, et al. Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: Retrospective analysis of hospital episode statistics in Scotland. BJOG 2011, 118(10): 1171-1179.
34. Altman D, Falconer C, Cnattingius S, Granath F. Pelvic organ prolapse surgery following hysterectomy on benign indications. Am J Obstet Gynecol 2008, 198: 572-578.
35. Forsgren C, Lundholm CT, Johansson AL, et al. Vaginal hysterectomy and risk of pelvic organ prolapse and stress urinary incontinence. Int Pelvic Floor Dysfunct 2012, 23: 43-48.
36. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002, 32(3 Suppl 1): 25-32.
37. Trelle S, Reichenbach S, Wandel S, Hildebrand P, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analy-sis. BMJ 2011, 342: 7086-9.
38. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. BJOG 1995, 100: 401-5.
39. Bonnar J, Sheppard BL. Treatments of menor-rhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996, 313: 579-82.
40. Lethaby AE, Cooke I, Rees M: Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005, 4 CD002126.
41. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009, 4: CD000154.
42. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009, (4): CD002120.
43. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod 2011, 26(10): 2698-2708.
44. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treat ment of heavy menstrual bleeding with estradiol valerate and die-nogest: a randomized controlled trial. Obstet Gynecol. 2011, 117(4): 777-787.
45. Ahrendt HJ, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/ levonorgestrel. Contraception, 2009, 80(5): 436-444.
46. Fraser IS, Parke S, Mellinger U, et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011, 16: 258-269.
47. Nappi RE, Terreno E, Sances G, et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with men-strually-related migraine (MRM). Contraception 2013, 88(3): 369-375.
48. Petraglia F, Parke S, Serrani M, et al. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. Int J Gynaecol Obstet 2014, 125(3): 270-274.
49. Jensen JT, Mellinger U, Serrani M, Mabey RG. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracept Reprod Health Care, 2013 18(4): 274-83.
50. Macias G, Merki-Feld GS, Parke S, et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol 2013, 33: 591-596.
51. Horie S, Harada T, Mitsunari M, et al. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 2005, 83: 1530-1535.
52. Mita S, Shimizu Y, Sato A, et al. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-a or interleukin-1p. Fertil Steril 2013, 101(2): 595-601.
53. Mita S, Shimizu Y, Notsu T, et al. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil Steril. 2011, 96(6): 1485-1489.
54. ACOG practice bulletin no. 110: noncontracep-tive uses of hormonal contraceptives. Obstet Gynecol 2010, 115: 206-218.
55. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menor-rhagia. Am J Obstet Gynecol 1991, 164(3): 879-883.
56. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006, 2: CD003855.
57. Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analy-sis. Obstet Gynecol 2009, 113: 1104-1116.
58. Herman MC, van den Brink MJ, Geomini PM, et al. Levonorgestrel Releasing Intrauterine System (Mirena) versus Endometrial Ablation (Novasure) in Women With Heavy Menstrual Bleeding: A Multicentre Randomised Controlled Trial BMC. Womens Health. 2013, 13: 32.
59. Hurskainen R, Teperi J, Rissanen P. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5 year follow-up. JAMA 2004, 291: 1456-63.
60. Heliovaara-Peippo S, Hurskainen R, Teperi J, et al. Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 2013, 209(6): 535.
61. Heliovaara-Peippo S, Halmesmaki K, Hurskainen R et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for men-orrhagia: a five-year randomized controlled trial. Acta Obstet Gynecol Scand., 2009, 88(12): 1389-96.
Review
For citations:
Chernukha GE, Ilyina LM. Inflammation - a biological basis for heavy menstrual bleeding, dysmenorrhea and CNS disorders. Integrated solution. Meditsinskiy sovet = Medical Council. 2015;(XX):20-27. (In Russ.) https://doi.org/10.21518/2079-701X-2015-XX-20-27
Views:
401
Email this article 